Tao Liu1, Joseph W Hogan, Michael J Daniels, Mia Coetzer, Yizhen Xu, Gerald Bove, Allison K DeLong, Lauren Ledingham, Millicent Orido, Lameck Diero, Rami Kantor. 1. *Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, RI; †Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya; Departments of ‡Statistics and Data Sciences; §Integrative Biology, University of Texas at Austin, Austin, TX; ‖Division of Infectious Diseases, the Alpert Medical School of Brown University, Providence, RI; and ¶Department of Medicine, School of Medicine, College of Health Sciences, Moi University, Eldoret, Kenya.
Abstract
OBJECTIVE: Improve pooled viral load (VL) testing to increase HIV treatment monitoring capacity, particularly relevant for resource-limited settings. DESIGN: We developed marker-assisted mini-pooling with algorithm (mMPA), a new VL pooling deconvolution strategy that uses information from low-cost, routinely collected clinical markers to determine an efficient order of sequential individual VL testing and dictates when the sequential testing can be stopped. METHODS: We simulated the use of pooled testing to ascertain virological failure status on 918 participants from 3 studies conducted at the Academic Model Providing Access to Healthcare in Eldoret, Kenya, and estimated the number of assays needed when using mMPA and other pooling methods. We also evaluated the impact of practical factors, such as specific markers used, prevalence of virological failure, pool size, VL measurement error, and assay detection cutoffs on mMPA, other pooling methods, and single testing. RESULTS: Using CD4 count as a marker to assist deconvolution, mMPA significantly reduces the number of VL assays by 52% [confidence interval (CI): 48% to 57%], 40% (CI: 38% to 42%), and 19% (CI: 15% to 22%) compared with individual testing, simple mini-pooling, and mini-pooling with algorithm, respectively. mMPA has higher sensitivity and negative/positive predictive values than mini-pooling with algorithm, and comparable high specificity. Further improvement is achieved with additional clinical markers, such as age and time on therapy, with or without CD4 values. mMPA performance depends on prevalence of virological failure and pool size but is insensitive to VL measurement error and VL assay detection cutoffs. CONCLUSIONS: mMPA can substantially increase the capacity of VL monitoring.
OBJECTIVE: Improve pooled viral load (VL) testing to increase HIV treatment monitoring capacity, particularly relevant for resource-limited settings. DESIGN: We developed marker-assisted mini-pooling with algorithm (mMPA), a new VL pooling deconvolution strategy that uses information from low-cost, routinely collected clinical markers to determine an efficient order of sequential individual VL testing and dictates when the sequential testing can be stopped. METHODS: We simulated the use of pooled testing to ascertain virological failure status on 918 participants from 3 studies conducted at the Academic Model Providing Access to Healthcare in Eldoret, Kenya, and estimated the number of assays needed when using mMPA and other pooling methods. We also evaluated the impact of practical factors, such as specific markers used, prevalence of virological failure, pool size, VL measurement error, and assay detection cutoffs on mMPA, other pooling methods, and single testing. RESULTS: Using CD4 count as a marker to assist deconvolution, mMPA significantly reduces the number of VL assays by 52% [confidence interval (CI): 48% to 57%], 40% (CI: 38% to 42%), and 19% (CI: 15% to 22%) compared with individual testing, simple mini-pooling, and mini-pooling with algorithm, respectively. mMPA has higher sensitivity and negative/positive predictive values than mini-pooling with algorithm, and comparable high specificity. Further improvement is achieved with additional clinical markers, such as age and time on therapy, with or without CD4 values. mMPA performance depends on prevalence of virological failure and pool size but is insensitive to VL measurement error and VL assay detection cutoffs. CONCLUSIONS: mMPA can substantially increase the capacity of VL monitoring.
Authors: Peter Piot; Salim S Abdool Karim; Robert Hecht; Helena Legido-Quigley; Kent Buse; John Stover; Stephen Resch; Theresa Ryckman; Sigrun Møgedal; Mark Dybul; Eric Goosby; Charlotte Watts; Nduku Kilonzo; Joanne McManus; Michel Sidibé Journal: Lancet Date: 2015-06-24 Impact factor: 79.321
Authors: Manuel Koller; Geoffrey Fatti; Benjamin H Chi; Olivia Keiser; Christopher J Hoffmann; Robin Wood; Hans Prozesky; Kathryn Stinson; Janet Giddy; Portia Mutevedzi; Matthew P Fox; Matthew Law; Andrew Boulle; Matthias Egger Journal: J Acquir Immune Defic Syndr Date: 2015-11-01 Impact factor: 3.731
Authors: Myres W Tilghman; Don Diego Guerena; Alexei Licea; Josué Pérez-Santiago; Douglas D Richman; Susanne May; Davey M Smith Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Olivia Keiser; Patrick MacPhail; Andrew Boulle; Robin Wood; Mauro Schechter; François Dabis; Eduardo Sprinz; Matthias Egger Journal: Trop Med Int Health Date: 2009-07-14 Impact factor: 2.622
Authors: Adam Brand; Susanne May; James P Hughes; Gertrude Nakigozi; Steven J Reynolds; Erin E Gabriel Journal: Stat Med Date: 2021-05-28 Impact factor: 2.497